This evidence guides immunotherapy targets for HCC, which were further explored by Qiu et al., who demonstrated ALKBH5’s complex role in TME in ICC, where it upregulates PD-L1 on mononuclear/macrophage cells and decreases myeloid inhibitory cell populations. This evidence concerns the gene ALKBH5 and hepatocellular carcinoma.